Biosimilar Competition: Early Learning

This study examines the early impact of biosimilar competition on biological drug pricing following the implementation of the Biologics Price Competition and Innovation Act (BPCIA) in 2010, finding that each additional biosimilar entrant reduces weighted average market prices by 5.4% to 7% through both originator price reductions and demand shifts to biosimilars. The authors conclude that while biosimilar competition has achieved measurable price reductions, these savings remain below initial expectations for moderating drug price growth in the biologic market.